Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

The Relationship between Metformin and Cancer in Patients with Type 2 Diabetes.

Chung HH, Moon JS, Yoon JS, Lee HW, Won KC.

Diabetes Metab J. 2013 Apr;37(2):125-31. doi: 10.4093/dmj.2013.37.2.125. Epub 2013 Apr 16.

2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings.

Bennett WL, Balfe LM, Faysal JM.

J Manag Care Pharm. 2012 Jan-Feb;18(1 Suppl A):1-22. Review.

4.

Metformin monotherapy for type 2 diabetes mellitus.

Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002966. Review. Update in: Cochrane Database Syst Rev. 2015;9:CD002966.

PMID:
16034881
5.

Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry.

Yang X, So WY, Ma RC, Kong AP, Xu G, Chan JC.

Diabetes Metab Res Rev. 2012 Jul;28(5):379-87. doi: 10.1002/dmrr.2287. Epub 2012 Feb 8. Review.

PMID:
22318884
6.

Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis.

Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, Kip KE.

Diabetes Care. 2011 Oct;34(10):2323-8. doi: 10.2337/dc11-0512. Review.

7.

Meta-analysis: metformin treatment in persons at risk for diabetes mellitus.

Salpeter SR, Buckley NS, Kahn JA, Salpeter EE.

Am J Med. 2008 Feb;121(2):149-157.e2. doi: 10.1016/j.amjmed.2007.09.016. Review.

PMID:
18261504
8.

[Diabetes and cancer risk: oncologic considerations].

Rosta A.

Orv Hetil. 2011 Jul 17;152(29):1144-55. doi: 10.1556/OH.2011.29158. Review. Hungarian.

PMID:
21712179

Supplemental Content

Support Center